Safety, Tolerance and Activity of HE3286 in Patients With Type 2 Diabetes Mellitus

ClinicalTrials.gov ID: NCT00694057

Public ClinicalTrials.gov record NCT00694057. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

View official ClinicalTrials.gov record → Back to search

ClinicalTrials.gov public records Last synced Oct 30, 2026, 12:05 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Phase II, Double Blind, Randomized, Placebo-Controlled Study of the Safety, Tolerance and Activity of HE3286 When Administered Orally for 12 Weeks to Adult Patients With Type 2 Diabetes Mellitus

Brief summary

Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.

This is a phase II, double-blind, randomized, placebo-controlled study of the safety, tolerance and activity of HE3286 in patients with type 2 diabetes mellitus. Patients receiving stable metformin or who are drug-naive will receive study treatment (HE3286 or placebo) for a treatment period of 12-weeks.

Study identification

NCT ID: NCT00694057
Recruitment status: Completed
Study type: Interventional
Phase: Phase 2
Lead sponsor: Harbor Therapeutics; Industry
Enrollment: 164 participants

Conditions and interventions

Conditions

Type 2 Diabetes Mellitus

Interventions

HE3286 Drug
Placebo Drug

Drug

Eligibility (public fields only)

Age range: 18 Years to 65 Years
Sex: All
Healthy volunteers: Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date: Jun 2008 (Type not available)
Primary completion: Jan 2010 (Actual)
Completion: Jan 2010 (Actual)
Last update posted: Jun 14, 2011

2008 – 2010

United States locations

U.S. sites: 22
U.S. states: 8
U.S. cities: 20

Facility	City	State	ZIP	Site status
Not listed	Anaheim	California	92801	—
Not listed	Anaheim	California	92805	—
Not listed	Beverly Hills	California	90211	—
Not listed	Buena Park	California	90620	—
Not listed	Burbank	California	91505	—
Not listed	Carmichael	California	95608	—
Not listed	Escondido	California	92025	—
Not listed	Fresno	California	93726	—
Not listed	Huntington Park	California	90255	—
Not listed	Long Beach	California	90806	—
Not listed	Los Angeles	California	90057	—
Not listed	National City	California	91950	—
Not listed	Roseville	California	95661	—
Not listed	Chicago	Illinois	60616	—
Not listed	Baton Rouge	Louisiana	70808	—
Not listed	St Louis	Missouri	63141	—
Not listed	Las Vegas	Nevada	89106	—
Not listed	Las Vegas	Nevada	89148	—
Not listed	El Paso	Texas	79905	—
Not listed	San Antonio	Texas	78229	—
Not listed	Salt Lake City	Utah	84107	—
Not listed	Kenosha	Wisconsin	53142	—

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows: Public field values for ClinicalTrials.gov record NCT00694057, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do: No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from: Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh: Last update posted Jun 14, 2011 · Synced Oct 30, 2026

Open the official record

The complete public registry record, listed eligibility criteria, and available contact information for NCT00694057 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →